批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2014/03/13 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
;Orphan
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2024/10/25 |
SUPPL-20(补充) |
Approval |
Labeling-Patient Package Insert,Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2022/01/20 |
SUPPL-14(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2022/01/13 |
SUPPL-15(补充) |
Approval |
Labeling-Package Insert,Labeling-Patient Package Insert |
STANDARD
|
|
|
| 2021/06/17 |
SUPPL-13(补充) |
Approval |
Efficacy-New Indication |
STANDARD
;Orphan
|
|
|
| 2021/05/31 |
SUPPL-12(补充) |
Approval |
Efficacy-New Patient Population |
STANDARD
|
|
|
| 2020/09/16 |
SUPPL-10(补充) |
Approval |
Labeling-Patient Package Insert,Labeling-Package Insert |
STANDARD
|
|
|
| 2019/03/11 |
SUPPL-7(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2019/02/21 |
SUPPL-8(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2018/01/04 |
SUPPL-5(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2016/09/09 |
SUPPL-4(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. |
| 2015/11/13 |
SUPPL-3(补充) |
Approval |
Labeling-Patient Package Insert,Labeling-Container/Carton Labels,Labeling-Package Insert |
STANDARD
|
|
|
| 2015/11/13 |
SUPPL-1(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:POSACONAZOLE; 剂型/给药途径:SOLUTION;INTRAVENOUS; 规格:300MG/16.7ML (18MG/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 205596 |
001 |
NDA |
NOXAFIL |
POSACONAZOLE |
SOLUTION;INTRAVENOUS |
300MG/16.7ML (18MG/ML) |
Prescription |
Yes |
Yes |
AP |
2014/03/13
|
MERCK SHARP DOHME |
| 208768 |
001 |
ANDA |
POSACONAZOLE |
POSACONAZOLE |
SOLUTION;INTRAVENOUS |
300MG/16.7ML (18MG/ML) |
Prescription |
No |
No |
AP |
2022/05/25
|
PH HEALTH |
| 209983 |
001 |
ANDA |
POSACONAZOLE |
POSACONAZOLE |
SOLUTION;INTRAVENOUS |
300MG/16.7ML (18MG/ML) |
Prescription |
No |
No |
AP |
2023/12/26
|
FRESENIUS KABI USA |
| 211500 |
001 |
ANDA |
POSACONAZOLE |
POSACONAZOLE |
SOLUTION;INTRAVENOUS |
300MG/16.7ML (18MG/ML) |
Prescription |
No |
No |
AP |
2023/12/26
|
MYLAN LABS LTD |
| 214842 |
001 |
ANDA |
POSACONAZOLE |
POSACONAZOLE |
SOLUTION;INTRAVENOUS |
300MG/16.7ML (18MG/ML) |
Prescription |
No |
No |
AP |
2023/12/26
|
EUGIA PHARMA |
| 217553 |
001 |
ANDA |
POSACONAZOLE |
POSACONAZOLE |
SOLUTION;INTRAVENOUS |
300MG/16.7ML (18MG/ML) |
Prescription |
No |
No |
AP |
2023/12/26
|
GLAND |
| 219057 |
001 |
ANDA |
POSACONAZOLE |
POSACONAZOLE |
SOLUTION;INTRAVENOUS |
300MG/16.7ML (18MG/ML) |
Prescription |
No |
No |
AP |
2024/12/23
|
ASPIRO |